umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Long-term safety and real world clinical experience of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the phase 3 ALSYMPCA study
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Show others and affiliations
2014 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 41, no suppl 2, S271-S271 p., OP506Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
2014. Vol. 41, no suppl 2, S271-S271 p., OP506
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:umu:diva-100990ISI: 000348841900357OAI: oai:DiVA.org:umu-100990DiVA: diva2:795402
Available from: 2015-03-16 Created: 2015-03-16 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Franzen, Lars
By organisation
Oncology
In the same journal
European Journal of Nuclear Medicine and Molecular Imaging
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 130 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf